ClinicalTrials.gg
Not yet recruitingNCT07689539Updated Jul 8, 2026

Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation

A Phase 3 interventional study of DN022150 and Chemotherapy in Pancreatic Cancer, sponsored by Jiangxi Kvvit Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by Jiangxi Kvvit Pharmaceutical Co., Ltd. (part of Qingfeng Pharmaceutical Group Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study plans to enroll participants with previously treated advanced pancreatic cancer and harbor centrally confirmed KRAS G12D mutation. Eligible participants will be randomized 1:1 to DN022150 Monotherapy or Investigator's Choice Chemotherapy

Read the detailed description

This study plans to enroll participants with previously treated advanced pancreatic cancer and harbor centrally confirmed KRAS G12D mutation. Eligible participants will be randomized 1:1 to DN022150 Monotherapy or Investigator's Choice Chemotherapy

02

Conditions studied

  • Pancreatic Cancer
03

In context

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,002 are open to participants now.

This study's planned enrollment of 360 is above the median of 47 across 2,932 interventional studies indexed under Pancreatic Neoplasms.

Browse Pancreatic Neoplasms studies →

Lead sponsor

Jiangxi Kvvit Pharmaceutical Co., Ltd. is the lead sponsor of 7 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily signed form
  2. Age 18-75 years (inclusive), male or female, at the time of signing informed consent
  3. ≥ 12 weeks
  4. Subjects with confirmed KRAS G12D who have received prior systemic therapy for advanced or pancreatic cancer
  5. score of performance status 0 \~ 1
  6. At least one by v1.1 criteria
  7. Adequate organ function
  8. Effective methods of during the study

Exclusion criteria

Exclusion Criteria:

  1. Progression or other requiring treatment within 5 years prior to enrollment
  2. Prior targeted therapy for KRAS G12D
  3. With central nervous system
  4. Uncontrolled fluid accumulation
  5. Other anticancer therapy within 4 or 5 half-lives (whichever is shorter) before treatment
  6. Concomitant cardiovascular disease
  7. Concurrent major acute or chronic infectious disease
  8. Subjects who have undergone other major surgery other than diagnostic or , or are expected to undergo major surgery during the study;
  9. History of severe mental or psychological illness or drug abuse or a history of severe alcohol abuse
  10. Other situations not suitable for the study judged by the investigator
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
360 participants (estimated)

Study arms

  • Experimental
    DN022150

    iv, QW, 28day/cycle

    Drug: DN022150

  • Active comparator
    Chemotherapy

    nal-IRI+5-FU/LV,AG or S-1

    Drug: Chemotherapy

Interventions

  • DrugDN022150

    iv QW 28-day/cycle

  • DrugChemotherapy

    Investigator's Choice of Chemotherapy: nal-IRI + 5-FU/LV, AG, or S-1

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    Evaluated by Blinded Independent Central Review (BIRC)

    Time frame: up to 2 years

  2. Overall Survival (OS)

    Time frame: up to 2 years

Secondary outcomes

  1. Progression-Free Survival (PFS)

    Evaluated by Investigator

    Time frame: up to 2 years

  2. Objective Response Rate (ORR)

    Time frame: up to 2 years

  3. Duration of Response (DoR)

    Time frame: up to 2 years

  4. Disease Control Rates (DCR)

    Time frame: up to 2 years

  5. Time to Response (TTR)

    Time frame: up to 2 years

  6. Incidence and severity of adverse events (AEs) graded by NCI-CTCAE v6.0

    Time frame: up to 2 years

  7. AUC0-t

    Time frame: Cycle2Day1 Cycle4Day1 Cycle8Day1 (28day/cycle)

  8. AUC0-inf

    Time frame: Cycle2Day1 Cycle4Day1 Cycle8Day1 (28day/cycle)

  9. Cmax

    Time frame: Cycle2Day1 Cycle4Day1 Cycle8Day1 (28day/cycle)

  10. Cmin

    Time frame: Cycle2Day1 Cycle4Day1 Cycle8Day1 (28day/cycle)

  11. t1/2

    Time frame: Cycle2Day1 Cycle4Day1 Cycle8Day1 (28day/cycle)

  12. EORTC QLQ-C30(European Organization for Research and Treatment of Cancer Quality of Life Questionnaire)

    scale 0-100,higher scores mean a worse outcome

    Time frame: up to 2 years

  13. EORTC QLQ-PAN26(European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Pancreatic Cancer 26)

    scale 0-100,higher scores mean a worse outcome

    Time frame: up to 2 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Jul 2028, 22 months later.

Of 84 phase 3 interventional studies under Pancreatic Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 77. This study's planned 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2026
First posted
Jul 8, 2026
StartEst.
Sep 2026
Primary completionEst.
Jul 2028
CompletionEst.
Dec 2028
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07689539
Responsible party
Sponsor
First posted
Jul 8, 2026
Start date
Sep 2026 (estimated)
Primary completion
Jul 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Jul 8, 2026

Study contacts

Xu Man
Contact
xuman@kvvit.com
+86 19979703650

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion